Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 72

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 72
---
arrants are exercisable upon FDA acceptance of an Investigational New Drug (IND) application for Telomir at $2.00 per share, for a period of 10-years. At Closing, the Warrants will be converted to warrants to purchase Telomir Common Stock at similar terms as the Warrants.

Treatment of TELI Options, RSUs and Warrants

TELI’s outstanding options, RSUs and warrants will not be affected by the Merger.

| 40 |

Representations and Warranties

The Merger Agreement contains representations and warranties that TELI and Merger Sub, on the one hand, and TELI, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if such statements made in the representations and warranties prove to be incorrect. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about TELI, TELI or Merger Sub, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between TELI and Merger Sub on the one hand, and TELI on the other hand.

Management Following the Merger

Following the Merger, the combined company is expected to retain four of the current directors of TELI as were in office prior to the Merger, comprised of Matthew Pratt Whalen, CPA; Erez Aminov; Edward MacPherson, and Dr. Matthew Paul Del Giudice, with each until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal

Regulatory Approvals

We are not aware of any federal, state, local or foreign regulatory requirements that must be complied with or approvals that must be obtained prior to completion of the merger pursuant to the merger agreement, other than compliance with applicable federal and state securities laws, the filing of articles of merger as required under the Florida Business Corporation Act and various state governmental authorizations.

Appraisal Rights and Dissenters’ Rights

Pursuant to Section 607.1302 of the Florida Business Corporation Act, the shareholders of TELI will not be entitled to appraisal rights or dissenters rights as a result of the merger.

Additional Information

For a detailed description of the Merger Agreement, including representations, warranties, covenants,